CLAIMS:

1. Use of a composition comprising an antigen and a saponin-based adjuvant in, or in the manufacture of a medicament for, intra-lung administration to a human or animal subject to elicit or induce an immune response in the subject.
2. The use of claim 1, wherein the medicament is formulated for intra-lung administration.
3. The use of claim 2, wherein the medicament is an aerosol or in dry powder form.
4. The use of claim 1, wherein the medicament is to be delivered to the subject by oral inhalation.
5. The use of claim 1, wherein the medicament is to be delivered to the lower lung of the subject.
6. The use of claim 1, wherein the medicament comprises an immunostimulating complex.
7. The use of claim 6, wherein the immunostimulating complex is formed of saponin, cholesterol and phospholipid.
8. The use of claim 1, wherein the medicament comprises an immunostimulating complex in combination with another immunostimulating adjuvant.
9. The use of claim 8, wherein the medicament comprises an immunostimulating complex in combination with a lipopolysaccharide adjuvant.
10. The use of claim 9, wherein the medicament comprises an immunostimulating complex formed of sapoin, cholesterol and phospholipid in combination with monophosphoryl lipid A (MPL).
11. The use of claim 1, wherein the antigen is an antigen which elicits or induces an immune response against a lung pathogen.
12. The use of claim 11, wherein the lung pathogen is influenza virus, Chlamydia pneumoniae, respiratory syncytial virus, or pneumococci.
13. The use of claim 1, wherein the antigen is an antigen which elicits or induces an immune response against a pathogen of non-lung mucosal sites.
14. The use of claim 13, in which the pathogen is Helicobacter pylori; Salmonella, E. coli, cholera, HIV, or a sexually transmitted disease organism.
15. The use of claim 1, wherein the antigen is a tumour specific or tumour associated antigen.

16. The use of claim 15, wherein the tumour is associated with a mucosal site.

17. The use of claim 16, wherein the tumour is a lung tumour, a tumour of the gastrointestinal tract, or a genital tract tumour.

18. The use of claim 1, substantially as hereinbefore described.

CLAIMS:

1. A method for eliciting or inducing an immune response in a human or animal subject, which comprises administering to said subject a composition comprising an antigen and an adjuvant, wherein the composition is administered to the subject by the intra-lung route.

2. The method of claim 1, wherein the composition is formulated for intra-lung administration.

3. The method of claim 2, wherein the composition is an aerosol or in dry powder form.

4. The method of claim 1, wherein the composition is delivered to the subject by oral inhalation.

5. The method of claim 1, wherein the composition is delivered to the lower lung of the subject.

6. The method of claim 1, wherein the composition comprises an immunostimulating adjuvant.

7. The method of claim 6, wherein the composition comprises at least one adjuvant selected from the group consisting of saponin-based adjuvants, liposomes, oil-in-water adjuvants, aluminium salt adjuvants, lipopolysaccharide adjuvants, oligonucleotide adjuvants and mucosal adjuvants.

8. The method of claim 6, wherein the composition comprises an immunostimulating complex.

9. The method of claim 8, wherein the composition comprises ISCOMATRIX™ adjuvant.

10. The method of claim 6, wherein the composition comprises an immunostimulating complex in combination with another immunostimulating adjuvant.

11. The method of claim 10, wherein the composition comprises an immunostimulating complex in combination with a lipopolysaccharide adjuvant.

12. The method of claim 11, wherein the composition comprises ISCOMATRIX™ adjuvant in combination with monophosphoryl lipid A (MPL).

13. The method of claim 1, wherein the antigen is an antigen which elicits or induces an immune response against a mucosal pathogen.

14. The method of claim 13, wherein the mucosal pathogen is influenza virus, Chlamydia pneumoniae, respiratory syncytial virus, or pneumococci.

15. The method of claim 1, wherein the antigen is an antigen which elicits or induces an immune response against a pathogen of non-mucosal sites.

16. The method of claim 15, in which the pathogen is Helicobacter pylori; Salmonella, E. coli, cholera, HIV, or a sexually transmitted disease organism.

17. The method of claim 1, wherein the antigen is a tumour specific or tumour associated antigen.

18. The method of claim 17, wherein the tumour is associated with a mucosal site.

19. The method of claim 18, wherein the tumour is a lung tumour, a tumour of the gastrointestinal tract, or a genital tract tumour.

20. Use of a composition comprising an antigen and an adjuvant in, or in the manufacture of a medicament for, intra-lung administration to a human or animal subject to elicit or induce an immune response in the subject.

21. An agent for eliciting or inducing an immune response in a human or animal subject by the intra-lung route, wherein said agent is a composition comprising an antigen and an adjuvant.